Biogen Idec Inc (BIIB)

BIIB (NASDAQ:Drugs)
$342.12
pos +5.73
+1.70%
Today's Range: 335.70 - 344.07 | BIIB Avg Daily Volume: 1,187,800
Last Update: 07/29/14 - 2:36 PM EDT
Volume: 933,474
YTD Performance: 20.32%
Open: $337.00
Previous Close: $336.39
52 Week Range: $203.55 - $358.89
Oustanding Shares: 236,144,705
Market Cap: 79,214,741,292
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 13 12 14
Moderate Buy 1 0 0 0
Hold 5 5 6 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.69 1.56 1.67 1.60
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 37.31
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
37.31 37.30 28.94
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
18.82% 50.69% 229.31%
GROWTH 12 Mo 3 Yr CAGR
Revenue 32.60 0.47 0.14
Net Income 34.90 1.07 0.27
EPS 35.70 0.97 0.25
Earnings for BIIB:
EBITDA 1.90B
Revenue 5.81B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $3.53 $3.66 $13.13 $16.77
Number of Analysts 1 1 1 1
High Estimate $3.53 $3.66 $13.13 $16.77
Low Estimate $3.53 $3.66 $13.13 $16.77
Prior Year $2.34 $2.33 $8.93 $13.13
Growth Rate (Year over Year) 50.85% 57.08% 47.03% 27.72%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

bullishBiogen Idec price target raised at Jefferies

Jul 24, 2014 | 8:10 AM EDT

BIIB price target raised from $380 to $410, Jefferies said. Buy rating. Company beat estimates due to strong Tysabri and Tecfidera sales.

bullishBiogen Idec numbers raised at Credit Suisse

Jul 24, 2014 | 7:48 AM EDT

Shares of BIIB now seen reaching $425, according to Credit Suisse. Estimates also increased, as management guided to higher Tecfidera growth. Outperform rating. 

By

Jim Cramer

 | Jul 24, 2014 | 6:38 AM EDT

In theory there should be plenty of shorting opportunities.

By

James "Rev Shark" DePorre

 | Jul 23, 2014 | 4:20 PM EDT

Too many people are willing to park cash in Microsoft or Apple.

By

Jim Cramer

 | Jul 23, 2014 | 1:54 PM EDT

McDonald's and GlaxoSmithKline are fighting against major turns of the tide.

By

Timothy Collins

 | Jul 7, 2014 | 2:33 PM EDT

This may be one of only two technical buying opportunities in 2014. 

updateBIIB Investor Mtg.

Jun 12, 2014 | 7:11 AM EDT

BIIB - Biogen Idec Inc. Annual Shareholder Meeting - 9AM

By

Jim Cramer

 | Jun 9, 2014 | 3:03 PM EDT

Become more aggressive about the real valuations of companies.

By

Jim Cramer

 | Jun 6, 2014 | 7:30 AM EDT

Shorts take much more homework than longs.

bullishBiogen Idec upgraded at JP Morgan

May 29, 2014 | 7:45 AM EDT

BIIB was upgraded from Neutral to Overweight, JP Morgan said. $375 price target. Company has multiple, mid-stage pipeline opportunities.

Panera Bread (PNRA) is due to report and had been hitting new 52-week lows recently. PNRA...
TSLA is trading $226.87, up 0.9% with IV30™ up 0.5%. This is an earnings preview, vo...
Going to be some big fireworks this week but we got it kick-started yesterday with some ca...
This one has met a minor target already, the next target comes in at 119.91-120.03, then 1...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.